Curadh and Alpha Fusion Join Forces to Innovate Astatine-211 Radiopharmaceuticals

In a significant collaboration, Curadh MTR Inc. and Alpha Fusion, Inc. are set to make waves in the field of cancer treatment. Both companies recently announced a strategic partnership aimed at advancing the clinical development of radiopharmaceutical products, particularly focusing on Astatine-211 (At-211)-based therapies. This partnership comes at a critical time as they prepare to present their findings at the upcoming 4th Targeted Radiopharmaceuticals Summit US, scheduled for later this month in San Diego.

Alison Armour, the Chief Medical Officer and founder of Curadh, will be leading a seminar titled Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development. Dr. Armour’s expertise remains pivotal as she reflects on her prior presentation at the recent World Astatine Community Meeting, highlighting the prospective importance of Astatine in the future of molecularly targeted radiopharmaceuticals. She noted, "Astatine's short half-life of 7.2 hours presents unique advantages over other radioisotopes, significantly reducing radiation exposure to patients, caregivers, and healthcare professionals."

Curadh has described Alpha Fusion as the only company globally with multiple At-211-based therapeutics currently undergoing clinical trials. Glenn Kazo, CEO of Curadh, expressed excitement about their emerging collaboration, acknowledging the substantial advancements achieved by Dr. Watabe and his team at Alpha Fusion in Japan. Their joint efforts are set to lay the groundwork for groundbreaking treatments that target various cancer types.

Prominent among the developments discussed was the recent presentation by Dr. Tadashi Watabe, M.D., Ph.D., from Osaka University. He presented initial data from a Phase I investigator-initiated clinical trial that confirmed the tolerability of At-211 and its potential efficacy in patients with radioiodine-refractory thyroid cancer. This promising development underscores the importance of Astatine in the therapeutic landscape, especially for those who have limited options due to treatment resistance.

Sunao Fujioka, CEO of Alpha Fusion, shared further insights: "With the rapid advancements in At-211 clinical development, we are thrilled to accelerate our entry into both U.S. and global markets. This progress is made viable through our partnership, fusing Alpha Fusion's innovative platform with Curadh's extensive expertise in radiopharmaceuticals."

As we look at the role of Astatine in contemporary medicine, it marks the dawn of potential for those affected by cancer. The integration of novel targets, alongside new radioisotopes, positions Curadh as a leader in advancing second-generation radiopharmaceuticals. Founded on the principles of innovative drug design, Curadh is helmed by an expert team who previously contributed to the clinical development of Pluvicto®, currently recognized as the leading radiopharmaceutical drug.

On the other hand, Alpha Fusion Co., Ltd. originated from pioneering research at Osaka University and the Japan Science and Technology Agency with the mission to revolutionize Astatine drug discovery. Their commitment to Targeted Alpha Therapy aims to maximize the therapeutic potential of Astatine while bringing hope to patients and families battling cancer.

The partnership between Curadh and Alpha Fusion signifies much more than just a collaborative effort; it reflects a unified front in the relentless pursuit of innovative cancer therapies. As advancements in this space unfold, both companies exemplify the spirit of scientific inquiry and dedication to improving patient outcomes across the globe.